This generic
clearance for FDA focus groups is approved for 18 months under the
following conditions: 1) FDA shall submit memos for individual
focus groups (e.g., statement of need, intended use of information,
description of respondents, information collection procedures,
justification for incentive, estimated burden, participant
screener, and moderator guide). 2) OMB will respond with clearance
or questions within 10 working days 3) OMB and FDA will jointly
evaluate the generic clearance upon resubmission in 18 months. Upon
resubmission, FDA will provide a summary of each collection
approved under the generic clearance (e.g., use of
information).
Inventory as of this Action
Requested
Previously Approved
11/30/2007
11/30/2007
05/31/2006
2,574
0
1,674
4,252
0
2,830
0
0
0
Information gathered from conducting
focus groups provides FDA with a more in-depthy understanding of
consumers attitudes, beliefs, motivations, and feelings than do
quantitiative studies. The information will be used to develop
programmatic proposals that are aligned with the respondents' input
and supplements other forms of public involvement.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.
Focus Groups as Used by the Food and Drug Administration